This company has been marked as potentially delisted and may not be actively trading. AzurRx BioPharma (AZRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AZRX vs. BLRX, SLGL, MRKR, HOOK, ASBP, GOVX, LEXX, BFRG, DRRX, and LPCNShould you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include BioLineRx (BLRX), Sol-Gel Technologies (SLGL), Marker Therapeutics (MRKR), Hookipa Pharma (HOOK), Aspire Biopharma (ASBP), GeoVax Labs (GOVX), Lexaria Bioscience (LEXX), Bullfrog AI (BFRG), DURECT (DRRX), and Lipocine (LPCN). AzurRx BioPharma vs. Its Competitors BioLineRx Sol-Gel Technologies Marker Therapeutics Hookipa Pharma Aspire Biopharma GeoVax Labs Lexaria Bioscience Bullfrog AI DURECT Lipocine BioLineRx (NASDAQ:BLRX) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking. Which has better valuation and earnings, BLRX or AZRX? AzurRx BioPharma has lower revenue, but higher earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$22.34M0.69-$60.61M-$8.80-0.53AzurRx BioPharmaN/AN/A-$32.67M-$11.50-0.05 Do institutionals & insiders hold more shares of BLRX or AZRX? 1.6% of BioLineRx shares are held by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 7.3% of AzurRx BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is BLRX or AZRX more profitable? AzurRx BioPharma has a net margin of 0.00% compared to BioLineRx's net margin of -90.57%. BioLineRx's return on equity of -163.37% beat AzurRx BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets BioLineRx-90.57% -163.37% -34.21% AzurRx BioPharma N/A -482.96%-258.47% Does the media favor BLRX or AZRX? In the previous week, BioLineRx had 2 more articles in the media than AzurRx BioPharma. MarketBeat recorded 2 mentions for BioLineRx and 0 mentions for AzurRx BioPharma. BioLineRx's average media sentiment score of 0.63 beat AzurRx BioPharma's score of 0.00 indicating that BioLineRx is being referred to more favorably in the media. Company Overall Sentiment BioLineRx Positive AzurRx BioPharma Neutral Does the MarketBeat Community favor BLRX or AZRX? BioLineRx received 284 more outperform votes than AzurRx BioPharma when rated by MarketBeat users. However, 74.26% of users gave AzurRx BioPharma an outperform vote while only 71.39% of users gave BioLineRx an outperform vote. CompanyUnderperformOutperformBioLineRxOutperform Votes50971.39% Underperform Votes20428.61% AzurRx BioPharmaOutperform Votes22574.26% Underperform Votes7825.74% Which has more volatility and risk, BLRX or AZRX? BioLineRx has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Do analysts rate BLRX or AZRX? BioLineRx presently has a consensus price target of $26.00, indicating a potential upside of 460.95%. Given BioLineRx's stronger consensus rating and higher possible upside, research analysts plainly believe BioLineRx is more favorable than AzurRx BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50AzurRx BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryBioLineRx beats AzurRx BioPharma on 11 of the 18 factors compared between the two stocks. Get AzurRx BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AZRX vs. The Competition Export to ExcelMetricAzurRx BioPharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.14M$6.88B$5.59B$8.51BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-0.058.5427.2019.68Price / SalesN/A262.76409.08153.66Price / CashN/A65.8538.3234.64Price / Book-0.736.526.974.61Net Income-$32.67M$143.48M$3.23B$248.06M AzurRx BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AZRXAzurRx BioPharmaN/A$0.55-3.4%N/A-72.4%$5.14MN/A-0.0512High Trading VolumeBLRXBioLineRx3.4776 of 5 stars$5.82-1.9%$26.00+346.7%-79.8%$19.38M$22.34M-0.6640Gap DownSLGLSol-Gel Technologies3.0315 of 5 stars$6.91-2.3%$40.00+478.9%-11.5%$19.25M$12.10M-20.3250Positive NewsShort Interest ↓MRKRMarker Therapeutics4.2853 of 5 stars$1.69-1.7%$13.17+679.1%-57.8%$19.12M$6.59M-1.2760HOOKHookipa Pharma3.163 of 5 stars$1.55+1.3%$4.50+190.3%-81.9%$18.89M$9.35M-0.4256Positive NewsASBPAspire BiopharmaN/A$0.38-4.6%N/AN/A$18.66MN/A0.00N/ANews CoverageGap DownGOVXGeoVax Labs3.4074 of 5 stars$1.22+3.4%$11.10+809.8%-23.1%$18.54M$5.59M-0.3310News CoverageGap DownLEXXLexaria Bioscience2.5389 of 5 stars$1.05+5.0%$7.00+566.7%-68.5%$18.44M$525.92K-2.107News CoverageBFRGBullfrog AI1.6717 of 5 stars$1.90+11.1%N/A-33.2%$17.89M$60K-2.244News CoverageDRRXDURECT1.3574 of 5 stars$0.58+4.0%N/A-59.0%$17.85M$1.86M-0.9480Positive NewsGap DownLPCNLipocine2.3266 of 5 stars$3.30-2.1%$9.00+172.7%-60.3%$17.66M$3.67M-4.3410News CoverageAnalyst ForecastAnalyst RevisionGap Down Related Companies and Tools Related Companies BLRX Alternatives SLGL Alternatives MRKR Alternatives HOOK Alternatives ASBP Alternatives GOVX Alternatives LEXX Alternatives BFRG Alternatives DRRX Alternatives LPCN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AZRX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AzurRx BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AzurRx BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AZRX Stock Free AZRX Stock Alerts